CA3176586A1 - Methods for treating polymicrobial infections - Google Patents

Methods for treating polymicrobial infections

Info

Publication number
CA3176586A1
CA3176586A1 CA3176586A CA3176586A CA3176586A1 CA 3176586 A1 CA3176586 A1 CA 3176586A1 CA 3176586 A CA3176586 A CA 3176586A CA 3176586 A CA3176586 A CA 3176586A CA 3176586 A1 CA3176586 A1 CA 3176586A1
Authority
CA
Canada
Prior art keywords
methods
treating
infections
polymicrobial infections
microbes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176586A
Other languages
French (fr)
Inventor
David A. Baunoch
Miguel F.R. Penaranda
Michael L. Opel
Maher BADIR
Natalie Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cap Diagnostics dba Pathnostics LLC
Original Assignee
Cap Diagnostics dba Pathnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/848,651 external-priority patent/US11053532B2/en
Priority claimed from US17/178,091 external-priority patent/US20210172000A1/en
Application filed by Cap Diagnostics dba Pathnostics LLC filed Critical Cap Diagnostics dba Pathnostics LLC
Publication of CA3176586A1 publication Critical patent/CA3176586A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods for detecting and treating polymicrobial infections, wherein a mixed population of microbes (e.g., bacteria) are present in a patient sample and the microbes are not first isolated from the sample. For example, the present invention describes specific polymicrobial infections and methods of treating said infections, wherein a particular antibiotic or a group of antibiotics are selected based on the composition of the polymicrobial infections.
CA3176586A 2020-04-14 2021-04-14 Methods for treating polymicrobial infections Pending CA3176586A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US16/848,651 US11053532B2 (en) 2017-04-19 2020-04-14 Methods for treating polymicrobial infections
US16/848,651 2020-04-14
US202063047846P 2020-07-02 2020-07-02
US63/047,846 2020-07-02
US202063063093P 2020-08-07 2020-08-07
US63/063,093 2020-08-07
US202063111287P 2020-11-09 2020-11-09
US63/111,287 2020-11-09
US202063119328P 2020-11-30 2020-11-30
US63/119,328 2020-11-30
US17/178,091 2021-02-17
US17/178,091 US20210172000A1 (en) 2017-04-19 2021-02-17 Methods and systems for preparing therapeutic solutions for polymicrobial infections
PCT/US2021/027336 WO2021211746A1 (en) 2020-04-14 2021-04-14 Methods for treating polymicrobial infections

Publications (1)

Publication Number Publication Date
CA3176586A1 true CA3176586A1 (en) 2021-10-21

Family

ID=78085362

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176586A Pending CA3176586A1 (en) 2020-04-14 2021-04-14 Methods for treating polymicrobial infections

Country Status (2)

Country Link
CA (1) CA3176586A1 (en)
WO (1) WO2021211746A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
FR2881755B1 (en) * 2005-02-10 2012-11-30 Biomerieux Sa MEDIA FOR THE SPECIFIC DETECTION OF RESISTANT MICROORGANISMS
AT503862B1 (en) * 2006-07-05 2010-11-15 Arc Austrian Res Centers Gmbh PATHOGENIC IDENTIFICATION DUE TO A 16S OR 18S RRNA MICROARRAY
EP2964785B8 (en) * 2013-03-04 2020-10-21 Fry Laboratories LLC Method and kit for characterizing microorganisms
US20180135108A1 (en) * 2014-01-20 2018-05-17 Board Of Trustees Of Michigan State University Method for detecting bacterial and fungal pathogens
EP3141612A1 (en) * 2015-09-10 2017-03-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method and device for nucleic acid based diagnostic approaches including the determination of a deviant condtion, especially a health condition and/or pathogenic condition of a sample
BR112019021943B1 (en) * 2017-04-19 2022-02-01 CAP Diagnostics, LLC, dba Pathnostics Methods to simultaneously determine the antibiotic susceptibilities of a mixed population of bacteria in samples
US11053532B2 (en) * 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections

Also Published As

Publication number Publication date
WO2021211746A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
Jørgensen et al. Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa
Stuart et al. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin
Sobke et al. Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline
Boyle et al. Low-virulence organisms and periprosthetic joint infection—biofilm considerations of these organisms
Liu et al. Tetrasodium EDTA is effective at eradicating biofilms formed by clinically relevant microorganisms from patients’ central venous catheters
Garg et al. Biofilm formation capability of enterococcal strains causing urinary tract infection vis-a-vis colonisation and correlation with enterococcal surface protein gene
Månsson et al. Sequence types of Staphylococcus epidermidis associated with prosthetic joint infections are not present in the laminar airflow during prosthetic joint surgery
Zmantar et al. Multiplex PCR detection of the antibiotic resistance genes in Staphylococcus aureus strains isolated from auricular infections
Kitti et al. Biofilm formation of methicillin-resistant coagulase-negative Staphylococci isolated from clinical samples in Northern Thailand
Bartoloni et al. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococi, enterococci and Clostridium difficile
Yaghoobi et al. Antibiofilm activity of Dracocephalum polychaetum extract on methicillin-resistant Staphylococcus aureus
Farhadian et al. Determination of vancomycin and methicillin resistance in clinical isolates of Staphylococcus aureus in Iranian hospitals.
Shahbazi et al. Zinc oxide nanoparticles impact the expression of the genes involved in toxin–antitoxin systems in multidrug‐resistant Acinetobacter baumannii
basil AbdulRazzaq et al. Detection of vanA and vanB genes Among Vancomycin Resistant Staphylococcus aureus Isolated from Clinical Samples in Baghdad Hospitals
Yamamichi et al. Relationship between urinary tract infection categorization and pathogens’ antimicrobial susceptibilities
CA3176586A1 (en) Methods for treating polymicrobial infections
Njoungang et al. Prevalence and antibiotic resistance patterns of strains of Staphylococcus aureus isolated at the Yaounde Military Hospital, Cameroon
Samra et al. Optimal detection of Staphylococcus aureus from clinical specimens using a new chromogenic medium
Torabi et al. Characteristics of methicillin resistant Staphylococcus aureus strains isolated from hospital wastewater in Tehran, Iran
WO2022251309A3 (en) Pharmaceutical compositions and uses thereof
Perez-Hernandez et al. Low prevalence of vancomycin-resistant enterococci in clinical samples from hospitalized patients of the Canary Islands, Spain
Fernández et al. Antimicrobial susceptibility of corynebacteria isolated from ewe's mastitis
Phillips et al. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria
El-Kady et al. The multi-drug resistance CFR gene: An evolving mechanism for linezolid resistance in Staphylococcus aureus
Al-Amara Comparison between phenotype and molecular resistance characteristic in Staphylococcus epidermidis isolates from wound infections in Al-Basrah province, Iraq

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922